Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” ...

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...